A two part study to separately evaluate the effect of 4-week treatment with GW501516X relative to placebo on cardiac energetics in a randomized, single-blind, repeat dose, parallel group design in healthy male subjects.

Trial Profile

A two part study to separately evaluate the effect of 4-week treatment with GW501516X relative to placebo on cardiac energetics in a randomized, single-blind, repeat dose, parallel group design in healthy male subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2012

At a glance

  • Drugs GW 501516 (Primary)
  • Indications Heart failure; Hyperlipidaemia
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Feb 2007 Status changed from recruiting to discontinued.
    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top